GRACELL BIOTECHNOLOGIES INC's ticker is GRCL and the CUSIP is 38406L103. A total of 37 filers reported holding GRACELL BIOTECHNOLOGIES INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $6,768,456 | -30.3% | 2,942,807 | -2.4% | 0.15% | -32.7% |
| Q3 2022 | $9,713,000 | -41.0% | 3,016,371 | +0.8% | 0.22% | -4.8% |
| Q2 2022 | $16,465,000 | +202.6% | 2,993,695 | +28.2% | 0.23% | +273.8% |
| Q1 2022 | $5,442,000 | -48.5% | 2,335,476 | +33.4% | 0.06% | -37.8% |
| Q4 2021 | $10,574,000 | -34.3% | 1,750,707 | +50.8% | 0.10% | -36.8% |
| Q3 2021 | $16,102,000 | +24.2% | 1,160,891 | +16.4% | 0.16% | +33.6% |
| Q2 2021 | $12,964,000 | -4.6% | 997,238 | +13.0% | 0.12% | -7.9% |
| Q1 2021 | $13,595,000 | – | 882,768 | – | 0.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 3,445,973 | $8,029,000 | 0.68% |
| Paradigm Biocapital Advisors LP | 783,445 | $1,825,000 | 0.48% |
| Orbimed Advisors | 7,884,870 | $18,372,000 | 0.30% |
| Vivo Capital, LLC | 961,359 | $2,240,000 | 0.15% |
| EcoR1 Capital, LLC | 1,559,710 | $3,634,000 | 0.11% |
| Temasek Holdings (Private) Ltd | 9,901,940 | $23,071,520 | 0.10% |
| Capital International, Inc./CA/ | 2,335,476 | $5,442,000 | 0.06% |
| Virtus ETF Advisers LLC | 24,728 | $58,000 | 0.03% |
| Capital International Sarl | 228,149 | $532,000 | 0.03% |
| FEDERATED HERMES, INC. | 1,298,578 | $3,026,000 | 0.01% |